NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of tumors. By utilizing copper isotopes - copper-61 for diagnostics and copper-67 for therapy - NUCLIDIUM is creating an innovative platform with the potential to overcome current limitations in the field of radiotheranostics. Operating in Switzerland and Germany, the company innovatively combines chemistry, deep clinical expertise and strategic manufacturing capabilities to provide scalable, accessible and clinically superior theranostic therapy solutions to patients worldwide. NUCLIDIUM's mission is to expand the reach and efficacy of radiotheranostics, addressing important unmet medical needs in the fields of oncology and women's health.
